The emergence of antibiotic-resistant bacteria is not a new topic; however, the urgency to discover and develop new high-impact products to prevent, diagnose and treat infections caused by them is high. In 2022, the world learned of the global burden of antibiotic-resistant bacteria from a paper published in the Lancet: in a single year (2019), 1.27 million deaths were directly attributable to infections caused by antibiotic-resistant bacteria, while an estimated 4.95 million deaths were associated with it. However, the visible clinical and preclinical pipeline of products to keep pace with the emergence of antibiotic-resistant bacteria is thin. CARB-X, a sponsored program at Boston University, is a global biopharmaceutical accelerator charged with building and supporting a pipeline of discovery and early-development projects and products of potential high-impact therapeutics, preventatives and diagnostics in this arena. Funded by four international governments (US, UK, DE and CA) and three foundations (the Wellcome Trust, the Bill and Melinda Gates Foundation and the Novo Nordisk Foundation), CARB-X is expected to deliver compelling products, primed for advanced development, for the infections (and bacteria that cause them) where the burden of mortality and morbidity are highest. The CARB-X model features non-dilutive funding and a novel support model that extends the project team to include the expertise necessary to advance a program from early-stage discovery and into clinical trials. From 1,400 initial applications, CARB-X has selected and accelerated 97 individual programs, covering traditional antibiotic programs, non-traditional treatment and prevention programs, vaccines and rapid diagnostics. After 6 full years of operation, CARB-X has initiated or completed 14 first-in-human studies for treatment and prevention, with several studies ongoing. Two of these programs are in advanced clinical-development studies. Two diagnostics have obtained CE marking, indicating that they are deemed to meet EU health, safety and environmental protection standards; 3 additional diagnostics are conducting clinical trials.